Market Overview

Leerink: Treasury Notice Lowers Pfizer-Allergan Deal Chances, Ownership Test Changes A 'Surprise'

Leerink: Treasury Notice Lowers Pfizer-Allergan Deal Chances, Ownership Test Changes A 'Surprise'
Related PFE
6 Big Pharma Companies Left To Report September Quarterly Figures
Pfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI
Should You Buy Pfizer Now? (Seeking Alpha)
Related AGN
Cramer Shares His Opinion On 8Point3 Energy, PPG Industries And Allergan
Barron's Picks And Pans: Super Chip Stocks, Time Warner And More
Allergan exercises option to buy Motus Therapeutics on promise of GI drug relamorelin (Seeking Alpha)

The U.S. Treasury’s latest move reduced the benefits of a deal between Pfizer Inc. (NYSE: PFE) and Allergan plc Ordinary Shares (NYSE: AGN), while limiting the number of corporate tax inversions.

Leerink’s Jason M. Gerberry noted that Pfizer’s break-up fee is now significantly lower, given the adverse changes in tax law, and the Notice “lowers the probability of the deal closing.”

Related Link: Betting On The Pfizer-Allergan Merger? You Now Have A 35% Arbitrage Opportunity After New Treasury Fears

Key Aspects To Consider

Analyst Jason Gerberry mentioned the key considerations regarding the Treasury update:

  • The Notice proposes a change in the "ownership test," which is used to determine Allergan’s ownership of the new entity formed by the merger, from more than 40 percent to mid-20 percent. This could fall below 20 percent, depending on certain assumptions. This suggests the risk of Pfizer owning more than 80 percent of the new entity and the deal not being considered as an inversion.
  • The Notice includes a provision regarding EPS stripping, “which we don’t see as a deal killer,” Gerberry wrote.
  • Although there are some legal questions regarding the implementation of the Notice, the reduction in breakup fee from $3.5 billion to $400 million could provide Pfizer with “sufficient reason to walk away.”


Leerink maintained a Market Perform rating for Pfizer. Reiterating an Outperform rating for Allergen, Gerberry recommended buying the shares “in any event [whether or not the deal gets completed] if the shares remain at pre-market levels (~$220/shr as of this writing).”

Latest Ratings for PFE

Oct 2016JefferiesDowngradesBuyHold
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jason M. Gerberry LeerinkAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (AGN + PFE)

View Comments and Join the Discussion!